Abstract
Improved glycemic control in type 2 diabetes (T2D) reduces the long-term risk of diabetes-related complications. This Canadian perspective study compared the relative cost and achievement of treatment targets with once-weekly semaglutide 1.0 mg vs. a broad range of other T2D treatments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
